TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16107168

Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcofluor white fluorescence
Number of subjects: 0
Study: 12131085

Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 88

Group type: COMPARATOR
Intervention: Coloplasty pouch (CP)
Number of subjects: 88
Study: 9844096

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anaerobic training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 7914409

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Other disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 46
Study: 2644747

Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg/kg i.v.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 16
Study: 811427

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (sublingual or oral)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 37
Study: 31711104

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (8 oz per day)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo (8 oz per day, matched constituents of pomegranate juice except for pomegranate polyphenols)
Number of subjects: 261
Study: 28732453

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (sunitinib, pazopanib, axitinib, sorafenib)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Adverse events of special interest treatment (pharmacologic and/or nonpharmacologic)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor dose management
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Neither treatment nor dose management
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Treatment for fatigue
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Prophylaxis for adverse events
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Treatment discontinuation due to adverse events
Number of subjects: 220
Study: 26323018

Group type: EXPERIMENTAL
Intervention: GEL (67.2 ± 7.2 g · h‐1 of CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: LIQ (67.8 ± 4.2 g · h‐1 of CHO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GEL
Number of subjects: 9

Group type: COMPARATOR
Intervention: LIQ
Number of subjects: 9
Study: 24423751

Group type: EXPERIMENTAL
Intervention: Stérimar Original
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sinus Rinse
Number of subjects: 18

Group type: COMPARATOR
Intervention: Emcur
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stérimar Original and Sinus Rinse
Number of subjects: 18
Study: 22466379

Group type: EXPERIMENTAL
Intervention: Power wheelchairs
Number of subjects: 28
Study: 19643656

Group type: EXPERIMENTAL
Intervention: Large amplitude of oscillations (forces between 50 and 200N)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Small amplitude of oscillations (150N‐200N)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quasi-static (maintained at 200N)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 30
Study: 18785289

Group type: EXPERIMENTAL
Intervention: Music during colonoscopy
Number of subjects: 722

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 722
Study: 15892401

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 695

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Transfused patients (Control)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Epoetin alfa and Routine care (Control)
Number of subjects: 695
Study: 12592245

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 60 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous-combined hormone therapy (conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous-combined hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 10566120

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.i.d. for four weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo tablets q.i.d. for four weeks
Number of subjects: 37
Study: 8606557

Group type: EXPERIMENTAL
Intervention: Survey sponsored by medical practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survey sponsored by university
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 1952005

Group type: EXPERIMENTAL
Intervention: oesophageal detector device
Number of subjects: 100
Study: 6119103

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metoprolol durules 200 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 160 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 320 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30753355

Group type: EXPERIMENTAL
Intervention: Primaquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylene Blue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Nongametocytocidal drugs)
Number of subjects: 0
Study: 28973682

Group type: EXPERIMENTAL
Intervention: Pituitary GammaKnife radiosurgery (160 Gy delivered in pituitary gland) associated with standards of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standards of care for pain according to recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pituitary GammaKnife radiosurgery
Number of subjects: 0
Study: 26981576

Group type: COMPARATOR
Intervention: Maraviroc (intervention in a randomized, placebo-controlled trial)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Not applicable (control group receiving placebo)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Not applicable (general findings from the study)
Number of subjects: 267
Study: 25155992

Group type: EXPERIMENTAL
Intervention: Psyllium (16 g total fiber/day)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) (16 g total fiber/day)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Gum arabic (GA) (16 g total fiber/day)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 189
Study: 22429436

Group type: EXPERIMENTAL
Intervention: Case scenario based seminar (intervention)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Primary care genetic counsellor (intervention)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: GC-managed appointments (intervention)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no seminar)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Secondary care genetic counsellor (control)
Number of subjects: 73
Study: 20610931

Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg per os TID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard azoles (fluconazole 400 mg per os OD, itraconazole 200 mg per os BID)
Number of subjects: 0
Study: 17693284

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ticarcillin/clavulanate
Number of subjects: 105
Study: 15644007

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 12373041

Group type: EXPERIMENTAL
Intervention: anti-Ox-LDL titer on admission
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: anti-Ox-LDL titer one month after admission
Number of subjects: 39

Group type: COMPARATOR
Intervention: anti-Ox-LDL titer on admission in patients with occluded IRA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: anti-Ox-LDL titer on admission in patients who underwent thrombolytic therapy
Number of subjects: 39
Study: 12219893

Group type: EXPERIMENTAL
Intervention: Reading background information about the issues to be discussed in the text material
Number of subjects: 0

Group type: COMPARATOR
Intervention: No background information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading background information about text sources
Number of subjects: 0
Study: 9833600

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily for 6 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Losartan 50 mg once daily for 6 weeks
Number of subjects: 25
Study: 8026247

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide 10 mg intravenously over 3 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide
Number of subjects: 20
Study: 2596070

Group type: EXPERIMENTAL
Intervention: Antioxidant complex (vitamins C, E, and A) administered preoperatively
Number of subjects: 197
Study: 335687

Group type: EXPERIMENTAL
Intervention: Pindolol (2 X 2 tablets per 5 mg daily) and Trichlormethiazidum (1 X 1 tablet per 4 mg daily)
Number of subjects: 74
Study: 30878103

Group type: EXPERIMENTAL
Intervention: Active ultrasound (2 MHz pulsed‐wave ultrasound for 120 min)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Sham ultrasound (control group)
Number of subjects: 676
Study: 28856858

Group type: EXPERIMENTAL
Intervention: HIFU treatment with SonoVue at 1 minute after administration
Number of subjects: 206

Group type: COMPARATOR
Intervention: HIFU treatment only (control group)
Number of subjects: 206
Study: 26324372

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once per day for 2 years
Number of subjects: 973

Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Erlotinib in EGFRm-positive subgroup
Number of subjects: 973

Group type: COMPARATOR
Intervention: Placebo in EGFRm-positive subgroup
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 973

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 973
Study: 23490328

Group type: EXPERIMENTAL
Intervention: ESBA105 6.4 mg (cohort III)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ESBA105 3.2 mg (cohorts II and IV)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ESBA105 (cohorts I, II, and IV)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ESBA105 (cohort IV)
Number of subjects: 79

Group type: COMPARATOR
Intervention: ESBA105
Number of subjects: 79
Study: 21609280

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caloric restriction with resistance training (CR+RT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 19358394

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 16428576

Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure of 15 mm Hg (group A)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intraabdominal pressure of 8-10 mm Hg (group B)
Number of subjects: 9
Study: 15213563

Group type: EXPERIMENTAL
Intervention: 2-dose intra-partum nevirapine in combination with standard antiretroviral therapy
Number of subjects: 891
Study: 11685612

Group type: EXPERIMENTAL
Intervention: Burr hole strict closed-system drainage (SCD); n=56
Number of subjects: 101

Group type: COMPARATOR
Intervention: Burr hole closed-system drainage with irrigation (CDI); n=45
Number of subjects: 101
Study: 9059217

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg kg‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study: 8322005

Group type: EXPERIMENTAL
Intervention: Toothpaste containing triclosan/silicone oil
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 33
Study: 3550162

Group type: EXPERIMENTAL
Intervention: EC/IC bypass with continuing medical care
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 1377
Study: 30601429

Group type: EXPERIMENTAL
Intervention: Laparoscopic technique under general anesthesia (LG)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Open surgery under combined anesthesia (OGE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Open surgery under general anesthesia (OG)
Number of subjects: 57
Study: 30408810

Group type: EXPERIMENTAL
Intervention: Low-salt (LS) diet (3.0 g/day of NaCl)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-salt (HS) diet (18.0 g/day of NaCl)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-salt (HS) diet
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-salt (LS) diet
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-salt (LS) and High-salt (HS) diets
Number of subjects: 44
Study: 26526662

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with albuminuria (≥ 30 mg/24 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with normoalbuminuria (<30 mg/24 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 60
Study: 24102685

Group type: EXPERIMENTAL
Intervention: Generic reference cleansers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference cleansers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Commercial skin cleansers
Number of subjects: 24
Study: 22103428

Group type: COMPARATOR
Intervention: Lidocaine (2.86 mg kg(‐1))
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tramadol-lidocaine (1 mg kg(‐1) and 2.46 mg kg(‐1))
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg kg(‐1))
Number of subjects: 7
Study: 20602575

Group type: EXPERIMENTAL
Intervention: exercise plus paroxetine 40 mg/day (n=21)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: exercise plus pill placebo (n=20)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: relaxation plus paroxetine (n=17)
Number of subjects: 75

Group type: COMPARATOR
Intervention: relaxation plus pill placebo (n=17)
Number of subjects: 75
Study: 18048817

Group type: EXPERIMENTAL
Intervention: Pelvic and prostate radiotherapy
Number of subjects: 444

Group type: COMPARATOR
Intervention: Prostate radiotherapy only
Number of subjects: 444
Study: 16079905

Group type: EXPERIMENTAL
Intervention: Mandatory minute ventilation (MMV) for 2 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV) for 2 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mandatory minute ventilation (MMV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 20
Study: 12571295

Group type: EXPERIMENTAL
Intervention: Functional ankle brace
Number of subjects: 100

Group type: COMPARATOR
Intervention: Below-the-knee cast
Number of subjects: 100
Study: 9869717

Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclip method
Number of subjects: 124

Group type: COMPARATOR
Intervention: Hypertonic saline-epinephrine (HSE) injection
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combined treatment (hemoclip + HSE)
Number of subjects: 124
Study: 8762418

Group type: EXPERIMENTAL
Intervention: Yuyang powder (YYP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cimetidine (Control)
Number of subjects: 200
Study: 2065700

Group type: EXPERIMENTAL
Intervention: Liv.52
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6134430

Group type: EXPERIMENTAL
Intervention: Sodium valproate (900-2400 mg/day, median 1700)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Biperiden (6-18 mg/day, median 12)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3577451

Group type: EXPERIMENTAL
Intervention: Tocolysis with Fenoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short TEDI (72 hours or less)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long TEDI (more than 72 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of obstetrical parameters between short and long TEDI groups
Number of subjects: 0
Study: 29214460

Group type: EXPERIMENTAL
Intervention: Blood flow restriction at 120 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood flow restriction at 200 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with 20 min recovery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with 5 min recovery
Number of subjects: 0
Study: 26882222

Group type: EXPERIMENTAL
Intervention: MobileKids Monster Manor (MKMM)
Number of subjects: 42
Study: 25340801

Group type: EXPERIMENTAL
Intervention: PXL01 in sodium hyaluronate
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 23863047

Group type: EXPERIMENTAL
Intervention: Cooled CoolSense device
Number of subjects: 177

Group type: COMPARATOR
Intervention: Non-cooled device (placebo)
Number of subjects: 177
Study: 19952830

Group type: COMPARATOR
Intervention: Water trial (500 mL of plain water)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bar trial (commercially available energy bar with 10 µg of 19‐norandrostenedione)
Number of subjects: 19
Study: 18410769

Group type: EXPERIMENTAL
Intervention: aP (acellular pertussis vaccine)
Number of subjects: 121

Group type: COMPARATOR
Intervention: HBV (hepatitis B vaccine)
Number of subjects: 121
Study: 16337501

Group type: EXPERIMENTAL
Intervention: Non-ischemic chronic heart failure
Number of subjects: 161

Group type: COMPARATOR
Intervention: Ischemic chronic heart failure
Number of subjects: 161
Study: 11941952

Group type: EXPERIMENTAL
Intervention: Omeprazole plus trimebutine for 3 months (Group A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Omeprazole for 3 months (Group B)
Number of subjects: 69
Study: 9853856

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 60
Study: 7847131

Group type: EXPERIMENTAL
Intervention: Intrathecal tissue plasminogen activator (rTPA) 10 mg in 10 ml solution, additional 5-10 mg for severe intraventricular bleeding
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no rTPA)
Number of subjects: 224
Study: 2480626

Group type: EXPERIMENTAL
Intervention: Standard protocol for refraction and visual acuity measurement
Number of subjects: 82
Study: 1107462

Group type: COMPARATOR
Intervention: benperidol
Number of subjects: 12

Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: cyproterone acetate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ethynyl oestradiol
Number of subjects: 12

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 12
Study: 29493476

Group type: EXPERIMENTAL
Intervention: Financial incentives and traffic-light labels
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no financial incentives or traffic-light labels)
Number of subjects: 148
Study: 27299699

Group type: EXPERIMENTAL
Intervention: DBT-based intervention (LIBER8)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Weight management group (2BFit)
Number of subjects: 45
Study: 25436213

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 105

Group type: COMPARATOR
Intervention: Carperitide
Number of subjects: 105
Study: 22765277

Group type: EXPERIMENTAL
Intervention: Gain-framed counseling
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Standard care messages
Number of subjects: 2032
Study: 20064838

Group type: EXPERIMENTAL
Intervention: Experimental group received counseling, nicotine patches, quit guide, plus information about cigarette characteristics
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group received counseling, nicotine patches, quit smoking guide
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Experimental materials
Number of subjects: 682
Study: 18328868

Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy for Diabetes (BFST‐D)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Educational Support Group (ES)
Number of subjects: 104
Study: 15882208

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic mouthwash
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-alcoholic mouthwash
Number of subjects: 30
Study: 12698207

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (10 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Number of subjects: 0
Study: 9925870

Group type: EXPERIMENTAL
Intervention: Early treatment with porcine surfactant (Curosurf)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Late treatment with porcine surfactant (Curosurf)
Number of subjects: 60
Study: 8781630

Group type: COMPARATOR
Intervention: Oral thyrotrophin-releasing hormone (TRH) and placebo
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lithium and placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lithium and TRH
Number of subjects: 19
Study: 1968726

Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cromoglycate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 369396

Group type: EXPERIMENTAL
Intervention: Lithium carbonate therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31349965

Group type: EXPERIMENTAL
Intervention: Enhanced caring communication style
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Enhanced structuring communication style
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard communication
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard structuring
Number of subjects: 148
Study: 29479010

Group type: COMPARATOR
Intervention: LDL-C target of < 2.07 mmol/L
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: LDL-C target of < 2.07 mmol/L and hs-CRP target of < 3 mg/L
Number of subjects: 400
Study: 26965492

Group type: EXPERIMENTAL
Intervention: 250 ml per day of orange juice (OJ) for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Energy and sugars-matched orange-flavoured drink (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 250 ml per day of orange juice (OJ)
Number of subjects: 36